Roy S Herbst, MD, PhD Professor of Medicine and Cancer Biology; Chief, Section of Thoracic Medical Oncology; Co-Chairman, Phase I Working Group, Department of Thoracic/ Head and Neck Medical Oncology Department of Cancer Biology The University of Texas MD Anderson Cancer Center Houston, Texas
	Click here to download entire interview
Track 1	Heading toward personalized medicine in lung cancer
Track 2	Performing biopsies in patients with advanced lung cancer
Track 3	Evaluation of tumor biomarkers in lung cancer
Track 4	Heterogeneity in biomarkers within tumors and across the disease spectrum
Track 5	Iressa® Pan-ASia Study (IPASS): First-line gefitinib versus carboplatin/paclitaxel for never/ oligosmokers with advanced adenocarcinoma of the lung
Track 6	Use of adjuvant tyrosine kinase inhibitors (TKIs) for patients with EGFR mutation-positive early lung cancer
Track 7	Increased EGFR gene copy number by FISH and outcome with cetuximab and chemotherapy in non-small cell lung cancer (NSCLC)
Track 8	Planned SWOG-S0819 trial: Carboplatin/paclitaxel with cetuximab in EGFR FISH-positive advanced NSCLC
Track 9	Expanding patient eligibility for treatment with bevacizumab in NSCLC
Track 10	Analysis of the risk-benefit ratio of chemotherapy with bevacizumab versus cetuximab for advanced NSCLC
Track 11	Combination therapy targeting VEGF and EGFR in NSCLC
Track 12	BETA: Improvement in progression-free survival with the addition of bevacizumab to erlotinib as second-line therapy for advanced NSCLC
Track 13	Identification of predictors of response to bevacizumab in lung cancer
Track 14	Improved time to progression with the multikinase inhibitor vandetanib compared to docetaxel in previously treated advanced NSCLC
Track 15	Tolerability and side effects of vandetanib
Track 16	ZODIAC: A Phase III study of docetaxel with or without vandetanib in locally advanced or metastatic NSCLC
Track 17	Assessment of EGFR and RAS mutations as predictors of response to vandetanib
Track 18	Assessment of the safety and tolerability of cediranib with etoposide and cisplatin as first-line therapy for extensive-stage or metastatic lung cancer

Primo N Lara Jr, MD Professor of Medicine Associate Director of Translational Research University of California Davis Cancer Center Sacramento, California
	Click here to download entire interview
Track 1	Mechanism of action of vascular disrupting agents (VDAs)
Track 2	DMXAA (ASA404): A second-generation small molecule flavenoid VDA
Track 3	Improved survival with DMXAA combined with carboplatin and paclitaxel for patients with Stage IIIB/IV NSCLC
Track 4	Phase III trial results with irinotecan/carboplatin versus oral etoposide/carboplatin in extensive-stage small cell lung cancer (ES-SCLC)
Track 5	SWOG-S0124: A Phase III trial of cisplatin/irinotecan versus cisplatin/etoposide in previously untreated ES-SCLC
Track 6	Interim results of a Phase III study of pemetrexed/carboplatin versus etoposide/carboplatin in previously untreated ES-SCLC
Track 7	Perspectives on recent randomized trial results in ES-SCLC
Track 8	Novel agents and biologic therapies under investigation in SCLC
Track 9	Pharmacodynamic separation strategy in studies of intermittent erlotinib and chemotherapy
Track 10	IPASS: First-line gefitinib versus chemotherapy for patients highly selected for response to EGFR TKIs
Track 11	SWOG-S0536: A Phase II trial of carboplatin/paclitaxel with cetuximab/bevacizumab followed by cetuximab/bevacizumab in advanced NSCLC
Track 12	Perspective on the FLEX trial: Cetuximab and cisplatin/vinorelbine (CV) versus CV alone as first-line therapy for advanced NSCLC overexpressing EGFR
Track 13	Perspective on the long-term survival results of IALT evaluating adjuvant cisplatin-based chemotherapy in NSCLC
Track 14	Prognostic and predictive role of excision repair cross-complementation group 1 (ERCC1) in lung cancer

Giuseppe Giaccone, MD, PhD Bethesda, Maryland
	Click here to download entire interview
Track 1	Immunotherapy for lung cancer
Track 2	Prevalence of EGFR mutations in Asians, and benefit from gefitinib compared to carboplatin/ paclitaxel in the IPASS trial
Track 3	Role of EGFR mutation status, FISH amplification and clinical characteristics in the selection of patients enriched for response to erlotinib
Track 4	Incidence of EGFR TKI-associated interstitial pneumonitis in Asian patients
Track 5	Use of adjuvant erlotinib off protocol for patients with EGFR mutations
Track 6	Correlation between skin rash and antitumor activity of EGFR TKIs
Track 7	Erlotinib dose escalation in smokers and patients with CNS metastases
Track 8	Perspective on the FLEX trial results with cisplatin/vinorelbine and cetuximab for advanced, EGFR-overexpressing NSCLC
Track 9	Use of cetuximab with chemoradiation therapy for locally advanced NSCLC
Track 10	Predictors of bevacizumab-associated hemoptysis
Track 11	ECOG-E1505 and potential mechanisms of action of bevacizumab in the adjuvant setting
Track 12	Potential role for the multikinase TKIs, including vandetanib, in NSCLC

Naiyer A Rizvi, MD Associate Attending Thoracic Oncology Department of Medicine Memorial Sloan-Kettering Cancer Center New York, New York
	Click here to download entire interview
Track 1	Advantages of neoadjuvant versus adjuvant therapy in NSCLC
Track 2	MSKCC studies of induction chemotherapy/erlotinib (ECON) in nonsmokers and chemotherapy/ bevacizumab (BEACON)
Track 3	Tumor regression with single-agent induction bevacizumab
Track 4	Use of cisplatin/docetaxel chemotherapy in the neoadjuvant and adjuvant settings
Track 5	Patients’ acceptance of long-term adjuvant therapy with EGFR TKIs
Track 6	Clinical and molecular markers as predictors of response to EGFR TKIs
Track 7	Clinical experience with first-line cetuximab-containing therapy for patients ineligible for bevacizumab
Track 8	Targeting EGFR and K-ras mutations in lung cancer
Track 9	Nonsquamous cell histology and benefit from first-line cisplatin and pemetrexed in advanced NSCLC
Track 10	Single-agent nanoparticle albumin-bound (nab) paclitaxel as initial therapy for patients with Stage IV NSCLC